PE20231169A1 - Metodos para el tratamiento de enfermedades cardiovasculares con ciclodextrinas - Google Patents
Metodos para el tratamiento de enfermedades cardiovasculares con ciclodextrinasInfo
- Publication number
- PE20231169A1 PE20231169A1 PE2023000716A PE2023000716A PE20231169A1 PE 20231169 A1 PE20231169 A1 PE 20231169A1 PE 2023000716 A PE2023000716 A PE 2023000716A PE 2023000716 A PE2023000716 A PE 2023000716A PE 20231169 A1 PE20231169 A1 PE 20231169A1
- Authority
- PE
- Peru
- Prior art keywords
- administration
- increase
- human subject
- compared
- amount
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063071257P | 2020-08-27 | 2020-08-27 | |
| PCT/US2021/048084 WO2022047249A1 (en) | 2020-08-27 | 2021-08-27 | Methods for the treatment of cardiovascular disease with cyclodextrins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20231169A1 true PE20231169A1 (es) | 2023-07-26 |
Family
ID=80353287
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2023000716A PE20231169A1 (es) | 2020-08-27 | 2021-08-27 | Metodos para el tratamiento de enfermedades cardiovasculares con ciclodextrinas |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20240000826A1 (https=) |
| EP (1) | EP4203974A4 (https=) |
| JP (1) | JP2023543131A (https=) |
| KR (1) | KR20230104119A (https=) |
| CN (1) | CN116322644A (https=) |
| AU (1) | AU2021331487A1 (https=) |
| CA (1) | CA3189915A1 (https=) |
| CO (1) | CO2023003656A2 (https=) |
| CR (1) | CR20230135A (https=) |
| IL (1) | IL300805A (https=) |
| JO (1) | JOP20230043A1 (https=) |
| MX (1) | MX2023002418A (https=) |
| PE (1) | PE20231169A1 (https=) |
| WO (1) | WO2022047249A1 (https=) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4877778A (en) * | 1987-07-01 | 1989-10-31 | The Children's Medical Center Corporation | Method of enhancing lipophile transport using cyclodextrin derivatives |
| CN104244956B (zh) * | 2012-04-13 | 2020-04-17 | L&F研究有限公司 | 使用环糊精的方法 |
-
2021
- 2021-08-27 CA CA3189915A patent/CA3189915A1/en active Pending
- 2021-08-27 CN CN202180053234.0A patent/CN116322644A/zh active Pending
- 2021-08-27 AU AU2021331487A patent/AU2021331487A1/en not_active Abandoned
- 2021-08-27 EP EP21862882.4A patent/EP4203974A4/en active Pending
- 2021-08-27 MX MX2023002418A patent/MX2023002418A/es unknown
- 2021-08-27 CR CR20230135A patent/CR20230135A/es unknown
- 2021-08-27 WO PCT/US2021/048084 patent/WO2022047249A1/en not_active Ceased
- 2021-08-27 PE PE2023000716A patent/PE20231169A1/es unknown
- 2021-08-27 IL IL300805A patent/IL300805A/en unknown
- 2021-08-27 JP JP2023513670A patent/JP2023543131A/ja active Pending
- 2021-08-27 KR KR1020237010388A patent/KR20230104119A/ko not_active Withdrawn
- 2021-08-27 US US18/023,325 patent/US20240000826A1/en active Pending
-
2022
- 2022-11-11 US US17/985,762 patent/US20230091966A1/en not_active Abandoned
-
2023
- 2023-02-27 JO JOJO/P/2023/0043A patent/JOP20230043A1/ar unknown
- 2023-03-23 CO CONC2023/0003656A patent/CO2023003656A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20240000826A1 (en) | 2024-01-04 |
| CO2023003656A2 (es) | 2023-08-09 |
| WO2022047249A1 (en) | 2022-03-03 |
| CA3189915A1 (en) | 2022-03-03 |
| JOP20230043A1 (ar) | 2023-02-27 |
| MX2023002418A (es) | 2023-07-11 |
| JP2023543131A (ja) | 2023-10-13 |
| CN116322644A (zh) | 2023-06-23 |
| US20230091966A1 (en) | 2023-03-23 |
| IL300805A (en) | 2023-04-01 |
| AU2021331487A1 (en) | 2023-03-16 |
| CR20230135A (es) | 2023-07-19 |
| EP4203974A4 (en) | 2024-08-07 |
| KR20230104119A (ko) | 2023-07-07 |
| EP4203974A1 (en) | 2023-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bawaskar et al. | Indian red scorpion envenoming | |
| CL2022002592A1 (es) | Uso de agentes para el tratamiento de condiciones respiratorias | |
| GT200900029A (es) | Metodos terapeuticos para el tratamiento de trastornos oculares vasculares con antagonistas de dii4 | |
| AR072805A1 (es) | Composiciones intranasales formas galenicas y metodos de tratamiento. | |
| Kaplan et al. | Role of ranolazine in heart failure: From cellular to clinic perspective | |
| WO2014116097A3 (es) | Composiciones para tratamiento sistémico de condiciones patológicas resultantes de estrés oxidativo y/o desequilibrio redox | |
| AR114392A1 (es) | Tratamiento de pacientes con enfermedad de fabry clásica | |
| Wang et al. | Hyperbaric Oxygen Improves Cerebral Ischemia/Reperfusion Injury in Rats Probably via Inhibition of Autophagy Triggered by the Downregulation of Hypoxia‐Inducing Factor‐1 Alpha | |
| PE20231169A1 (es) | Metodos para el tratamiento de enfermedades cardiovasculares con ciclodextrinas | |
| Wallmüller et al. | Limited effect of mild therapeutic hypothermia on outcome after prolonged resuscitation | |
| Bergman et al. | Escitalopram for antipsychotic nonresponsive visual hallucinosis: eight patients suffering from Charles Bonnet syndrome | |
| GT200600274A (es) | Amidas sustituidas con heteroarilo que comprenden un grupo enlazador saturado y su uso como agentes farmacétuicos | |
| ZHANG et al. | Effect of moxibustion on SIRT1/eNOS signaling pathway in ApoE-/-atherosclerotic mice | |
| Cofan et al. | Quality of life in renal transplant recipients following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium | |
| AR061635A1 (es) | Tratamiento de insuficiencia cardiaca cronica leve en pacientes humanos | |
| RU2295349C2 (ru) | Способ лечения остеоартроза коленных суставов с использованием внутрисуставного введения препарата "хондролон" | |
| Sfera et al. | Love in the Time of COVID: Psychiatric Outcomes Related to Oxytocin and the “Endocrine Organ” | |
| CL2025003377A1 (es) | Tratamiento de afecciones inflamatorias que comprende imu-856. | |
| Oh et al. | An intriguing case of primary amyloidosis with cardiac involvement: symptomatic and echocardiographic improvement with thalidomide treatment | |
| Ziga-Martínez et al. | Catastrophic presentation of venous thromboembolic disease | |
| Audette | Acupuncture-Immune Modulation and the Gut-Lung Axis | |
| Nangana et al. | Efficacy of AMXs, Natural Filaggrin and TNF-alpha Modulators containing V. amygdalina leaf Extracts, on Inflammatory Skin Diseases | |
| Menichelli et al. | Role of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in heart failure with reduced and preserved ejection fraction | |
| Parkhomenko et al. | Improving efficiency of antioxidant and cytoprotective therapy in patients with NSAID-gastropathy and concomitant ischemic heart disease | |
| WO2006076119A3 (en) | Treatment of skin diseases |